SCHEMBL2175586

SCHEMBL2175586

COc1cc2nccc(Oc3ccc(CC(=O)Nc4nc(C)cs4)cc3)c2cc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
MAPK10 P53779 1/20 0.55
CSF1R P07333 3/20 0.55
PDGFRB P09619 3/20 0.55
FLT3 P36888 3/20 0.55
KDR P35968 3/20 0.55
AXL P30530 2/20 0.53
MERTK Q12866 2/20 0.53
FLT4 P35916 1/20 0.52
PDGFRA P16234 5/20 0.51
KIT P10721 3/20 0.51
RAB9A P51151 2/20 0.50
WNT3A P56704 1/20 0.50
ALDH1A1 P00352 1/20 0.50
RET P07949 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173153 0.93 SMN1; SMN2 (0.55) METSMN1; SMN2KDM4ELMNATSHR
SCHEMBL2176128 0.92 MET (0.64) METSMN1; SMN2KDM4ELMNATSHR
SCHEMBL5610715 0.85 SMN1; SMN2 (0.55) METSMN1; SMN2KDM4ELMNATSHR
SCHEMBL1097598 0.79 PDGFRB (0.65) SMN1; SMN2KDM4ELMNATSHRMAPK1
SCHEMBL2172313 0.79 PDGFRB (0.57) METCSF1RPDGFRBFLT3KDR
SCHEMBL2174528 0.78 FLT3 (0.64) METCSF1RPDGFRBFLT3KDR
SCHEMBL2173476 0.78 PDGFRB (0.67) METCSF1RPDGFRBFLT3KDR
SCHEMBL2177519 0.78 PDGFRB (0.66) METCSF1RPDGFRBFLT3KDR
SCHEMBL2177123 0.77 PDGFRB (0.86) METCSF1RPDGFRBFLT3KDR
SCHEMBL2176728 0.76 PDGFRB (0.62) METCSF1RPDGFRBFLT3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 MET 3334/4885SMN1; SMN2 2298/4885KDM4E 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.